Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525774 | 0.91 | CYP2B6 (0.47) | CYP2B6MAPTKMT2ALMNACHRM3 | |
| SCHEMBL10360491 | 0.78 | MAPT (0.43) | MAPTKMT2ALMNACHRM3KCNN4 | |
| SCHEMBL9273398 | 0.76 | KMT2A (0.46) | MAPTKMT2ACHRM3 | |
| SCHEMBL7545842 | 0.75 | KIF11 (0.40) | CYP2B6MAPTKMT2ALMNAGAA | |
| SCHEMBL10360494 | 0.75 | MAPT (0.38) | CYP2B6MAPTKMT2ALMNACHRM3 | |
| SCHEMBL10360472 | 0.74 | MAPT (0.46) | MAPTKMT2ALMNACHRM3KCNN4 | |
| SCHEMBL6266546 | 0.70 | CYP2B6 (0.56) | CYP2B6MAPTKMT2ACHRM3 | |
| SCHEMBL7559824 | 0.69 | KCNN4 (0.51) | CYP2B6MAPTKMT2ALMNACHRM3 | |
| Cadaverine Tartrate SCHEMBL27624850 | 0.69 | KEAP1 (0.58) | CHRM3KIF11 | |
| Cadaverine Tartrate SCHEMBL28092955 | 0.68 | MAPT (0.45) | MAPTKMT2ALMNAKCNN4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS U.S.A. INC. FOR BARBADOS | 2008-09-11 | — | — | US | disclosed |
| EP-1966179-A2 | DARIFENACIN HYDROBROMIDE COMPOSITION SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2008-09-10 | — | — | EP | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | disclosed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076159-A2 | PURE DARIFENACIN HYDROBROMIDE SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | CHRM3 2/4885CYP2B6 2672/4885MAPT 2830/4885 |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CYP2B6 667/4885MAPT 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.